James J. Mulé

16.4k total citations · 5 hit papers
167 papers, 12.8k citations indexed

About

James J. Mulé is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, James J. Mulé has authored 167 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Immunology, 97 papers in Oncology and 45 papers in Molecular Biology. Recurrent topics in James J. Mulé's work include Immunotherapy and Immune Responses (97 papers), Immune Cell Function and Interaction (47 papers) and Cancer Immunotherapy and Biomarkers (45 papers). James J. Mulé is often cited by papers focused on Immunotherapy and Immune Responses (97 papers), Immune Cell Function and Interaction (47 papers) and Cancer Immunotherapy and Biomarkers (45 papers). James J. Mulé collaborates with scholars based in United States, France and Malaysia. James J. Mulé's co-authors include Steven A. Rosenberg, S A Rosenberg, Koïchi Shimizu, Paul J. Spiess, Shari Pilon‐Thomas, Ryan C. Fields, Nicholas P. Restifo, Susan Schwarz, Suyu Shu and Cheryl M. Reichert and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

James J. Mulé

163 papers receiving 12.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

2005 813 citations Shari Pilon‐Thomas, James J. Mulé et al. profile →
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1985 593 citations James J. Mulé, Paul J. Spiess et al. The Journal of Experimental Medicine profile →
Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1984 560 citations James J. Mulé, Steven A. Rosenberg et al. profile →
Identification of human cancers deficient in antigen processing.

1993 522 citations James J. Mulé, Steven A. Rosenberg et al. The Journal of Experimental Medicine profile →
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy

2016 468 citations Shari Pilon‐Thomas, Krithika N. Kodumudi et al. Cancer Research profile →

Peers

Countries citing papers authored by James J. Mulé

Since Specialization

Citations

This map shows the geographic impact of James J. Mulé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James J. Mulé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James J. Mulé more than expected).

Fields of papers citing papers by James J. Mulé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James J. Mulé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James J. Mulé. The network helps show where James J. Mulé may publish in the future.

Co-authorship network of co-authors of James J. Mulé

This figure shows the co-authorship network connecting the top 25 collaborators of James J. Mulé. A scholar is included among the top collaborators of James J. Mulé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James J. Mulé. James J. Mulé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), Leticia Tordesillas, Matthew Beatty, (unknown), (unknown), Dongliang Du, (unknown), (unknown), Bradford A. Perez, Anders Berglund, Y. Ann Chen, Amod A. Sarnaik, James J. Mulé, Ben Creelan, Shari Pilon‐Thomas, Daniel Abate‐Daga	4
2	RNF135 Expression Marks Chemokine (C-C Motif) Ligand-Enriched Macrophage–Tumor Interactions in the Glioblastoma Microenvironment 2025 ·Cancers ·Jianan Chen, Qiong Wu, Anders Berglund, Robert Macaulay, James J. Mulé, Arnold B. Etame	1
3	Evaluating the Radiation Sensitivity Index and 12-Chemokine Gene Expression Signature for Clinical Use in a CLIA Laboratory 2025 ·Cancer Research Communications ·Anders Berglund, John Puskas, Sean Yoder, (unknown), Douglas C. Marchion, Dahui Qin, James J. Mulé, Javier F. Torres–Roca, Steven A. Eschrich	2
4	Phase Ib neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC). 2023 ·Journal of Clinical Oncology ·Roger Li, Philippe E. Spiess, Wade J. Sexton, Michael Poch, Logan Zemp, Julio M. Pow‐Sang, Jingsong Zhang, Jasreman Dhillon, (unknown), (unknown), (unknown), James M. Burke, James J. Mulé, José R. Conejo-García, Rohit Jain	1
5	Epigenetic state determines the in vivo efficacy of STING agonist therapy 2023 ·Nature Communications ·Rana Falahat, Anders Berglund, Patricio Perez-Villarroel, Ryan M. Putney, Imène Hamaidi, (unknown), Shari Pilon‐Thomas, Glen N. Barber, James J. Mulé	56
6	Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response 2020 ·Cancers ·Saurabh Garg, Eric A. Welsh, Bin Fang, (unknown), Trevor Rose, Jhanelle E. Gray, John M. Koomen, Anders Berglund, James J. Mulé, Joseph Markowitz	8
7	STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity 2019 ·Cancer Immunology Research ·Rana Falahat, Patricio Perez-Villarroel, Adam W. Mailloux, Genyuan Zhu, Shari Pilon‐Thomas, Glen N. Barber, James J. Mulé	67
8	Methylation of immune synapse genes modulates tumor immunogenicity 2019 ·Journal of Clinical Investigation ·Anders Berglund, Matthew N. Mills, Ryan M. Putney, Imène Hamaidi, James J. Mulé, Sungjune Kim	30
9	Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma 2017 ·Journal of the National Comprehensive Cancer Network ·T. Ström, Javier F. Torres–Roca, Akash D. Parekh, A.O. Naghavi, Jimmy J. Caudell, Daniel Oliver, Jane L. Messina, Nikhil I. Khushalani, Jonathan S. Zager, Amod A. Sarnaik, James J. Mulé, Andy Trotti, Steven A. Eschrich, Vernon K. Sondak, Louis B. Harrison	24
10	Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy breakdown → 2016 ·Cancer Research ·Shari Pilon‐Thomas, Krithika N. Kodumudi, Asmaa El-Kenawi, Shonagh Russell, Amy Weber, Kimberly A. Luddy, Mehdi Damaghi, Jonathan W. Wojtkowiak, James J. Mulé, Arig Ibrahim‐Hashim, Robert J. Gillies	468
11	BIRC3 is a novel driver of therapeutic resistance in Glioblastoma 2016 ·Scientific Reports ·Dapeng Wang, Anders Berglund, Rajappa S. Kenchappa, Peter Forsyth, James J. Mulé, Arnold B. Etame	71
12	Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma 2010 ·The Journal of Immunology ·Shari Pilon‐Thomas, (unknown), Nasreen A. Vohra, James J. Mulé	117
13	Inducible Expression of Macrophage Receptor Marco by Dendritic Cells Following Phagocytic Uptake of Dead Cells Uncovered by Oligonucleotide Arrays 2003 ·The Journal of Immunology ·(unknown), David E. Misek, Rork Kuick, Samir Hanash, James J. Mulé	42
14	Making room for T cells 2002 ·Journal of Clinical Investigation ·Gabriel N. Maine, James J. Mulé	3
15	Making room for T cells 2002 ·Journal of Clinical Investigation ·Gabriel N. Maine, James J. Mulé	50
16	A Rapid and Quantitative Assay to Estimate Gene Transfer into Retrovirally Transduced Hematopoietic Stem/Progenitor Cells Using a 96-Well Format PCR and Fluorescent Detection System Universal for MMLV-Based Proviruses 1996 ·Human Gene Therapy ·(unknown), (unknown), Gregg P. Solar, James J. Mulé, William G. Kerr	37
17	Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. 1991 ·The Journal of Experimental Medicine ·Richard J. Barth, James J. Mulé, Paul J. Spiess, Steven A. Rosenberg	348
18	Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-γ and tumor necrosis factor 1991 ·Journal of Immunological Methods ·Richard J. Barth, James J. Mulé, Anthony L. Asher, Martin G. Sanda, Steven A. Rosenberg	17
19	Induction of Interferon‐β₂/Interleukin‐6 (IL‐6) by Cytokine Administration and Detection of Circulating Interleukin‐6 in the Tumor‐bearing State 1989 ·Annals of the New York Academy of Sciences ·David M. Jablons, Joe McIntosh, James J. Mulé, Richard P. Nordan, Stuart Rudikoff, Michael T. Lotze	30
20	Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. 1987 ·The Journal of Experimental Medicine ·James J. Mulé, Craig A. Smith, Steven A. Rosenberg	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact